Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

234 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02. In addition, the kinetics of the antibody response will be evaluated in a subset of participants who will receive a booster dose of Menactra® vaccine and children in the same age group not previously vaccinated with a meningococcal vaccine or had meningitis disease who will receive a dose of Menactra® vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

NCT00269477

Meningitis Meningococcal Infection

COMPLETED PHASE2

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277

Meningococcal Infections Meningitis

COMPLETED

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

NCT00700713

Meningitis Meningococcemia

COMPLETED PHASE2

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

NCT00728260

Meningitis Meningococcal Disease

COMPLETED

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996

Meningitis Meningococcal Infection Diphtheria +3 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningitis Meningococcal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Menactra® Group 1

Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.

Group Type EXPERIMENTAL

Polysaccharide Diphtheria Conjugate Vaccine

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Menactra® Group 2

Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.

Group Type EXPERIMENTAL

Polysaccharide Diphtheria Conjugate Vaccine

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Meningococcal Vaccine-naïve Group 3

Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.

Group Type EXPERIMENTAL

Polysaccharide Diphtheria Conjugate Vaccine

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Meningococcal Vaccine-naïve Group 4

Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.

Group Type EXPERIMENTAL

Polysaccharide Diphtheria Conjugate Vaccine

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polysaccharide Diphtheria Conjugate Vaccine

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Polysaccharide Diphtheria Conjugate Vaccine

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Polysaccharide Diphtheria Conjugate Vaccine

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Polysaccharide Diphtheria Conjugate Vaccine

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Menactra® Menactra® Menactra® Menactra®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is healthy, as determined by medical history.
* Subject is between the ages of 7 and 15 years (not yet 16 years).
* For subjects who participated in Study 603-02, subject previously received one dose of Menactra® vaccine or Menomune®-A/C/Y/W-135 vaccine.
* The date of vaccination during Study 603-02 will have occurred 5 years ± 6 months before the collection of the blood sample obtained for Study MTA23.
* A negative urine pregnancy test is required for menstruating female subjects.
* Parent/legal guardian has signed an Institutional Review Board (IRB)-approved informed consent form and subject has signed an IRB-approved assent form.

Exclusion Criteria

* Subjects who participated in sanofi pasteur Study MTA17 Stage I (a subset of subjects from Study 603-02 who had been recruited for the follow-up challenge study)
* History of documented invasive meningococcal disease
* Received any other meningococcal vaccine
* Received any vaccine in the 28-day period prior to enrollment
* Received antibiotic therapy within the 72 hours prior to collection of a blood sample
* Actively enrolled or scheduled to be enrolled in another clinical study
* Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, psychiatric, or other organ system)
* Known or suspected impairment of immunologic function
* Acute medical illness with or without fever within 72 hours or an oral temperature ≥ 100.4°F (≥ 38.0°C) at the time of inclusion
* Scheduled to receive any vaccination in the 7-day or 14-day period after enrollment
* Administration of immune globulin, other blood products, or corticosteroid within 8 weeks (56 days) of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
* Personal of family history of Guillain-Barres Syndrome
* Suspected or known hypersensitivity to any of the vaccine components
* Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
* Any condition which, in the opinion of the investigator, would pose a health risk to the participant.

Minimum Eligible Age

7 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes